We are live on ! Find out more
ACRV icon

Acrivon Therapeutics
ACRV

44 hedge funds and large institutions have $22.6M invested in Acrivon Therapeutics in 2026 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 11 increasing their positions, 11 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 11

8% less funds holding

Funds holding: 48 → 44 (-4)

17.07% less ownership

Funds ownership: 58.98% → 41.91% (-17%)

23% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 13

50% less capital invested

Capital invested by funds: $44.9M → $22.6M (-$22.3M)

Holders
44
Holders Change
-4
Holders Change %
-8.33%
% of All Funds
0.54%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
10
Increased
11
Reduced
11
Closed
13
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$462K
2
GCP
GSA Capital Partners
United Kingdom
+$326K
3
Renaissance Technologies
Renaissance Technologies
New York
+$217K
4
BCM
Bridgeway Capital Management
Texas
+$202K
5
Marshall Wace
Marshall Wace
United Kingdom
+$112K

Top Sellers

1
Citadel Advisors
Citadel Advisors
Florida
-$3.96M
2
ACA
Acorn Capital Advisors
New York
-$977K
3
UBS Group
UBS Group
Switzerland
-$548K
4
Two Sigma Investments
Two Sigma Investments
New York
-$341K
5
Millennium Management
Millennium Management
New York
-$293K
Name Holding Trade Value Shares
Change 		Change in
Stake
RCM
1
RA Capital Management
Massachusetts
$11.6M – – –
SCV
2
Sands Capital Ventures
Virginia
$2.95M – – –
Wellington Management Group
3
Wellington Management Group
Massachusetts
$1.23M – – –
Acadian Asset Management
4
Acadian Asset Management
Massachusetts
$1.18M +$462K +264,765 +46%
Renaissance Technologies
5
Renaissance Technologies
New York
$1.05M +$217K +124,271 +20%
VCM
6
Vanguard Capital Management
Pennsylvania
$1M +$1.26M +722,035 New
Marshall Wace
7
Marshall Wace
United Kingdom
$779K +$112K +64,355 +13%
Two Sigma Investments
8
Two Sigma Investments
New York
$541K -$341K -195,674 -33%
Jane Street
9
Jane Street
New York
$333K -$179K -102,380 -30%
Geode Capital Management
10
Geode Capital Management
Massachusetts
$329K +$66.6K +38,168 +19%
BlackRock
11
BlackRock
New York
$290K +$6.66K +3,815 +2%
GCP
12
GSA Capital Partners
United Kingdom
$260K +$326K +186,716 New
BCM
13
Bridgeway Capital Management
Texas
$221K +$202K +116,000 +270%
VFT
14
Vanguard Fiduciary Trust
Pennsylvania
$149K +$188K +107,529 New
State Street
15
State Street
Massachusetts
$93.3K – – –
XT
16
XTX Topco
Cayman Islands
$93K +$80.8K +46,310 +225%
Northern Trust
17
Northern Trust
Illinois
$68K -$25.8K -14,816 -23%
Morgan Stanley
18
Morgan Stanley
New York
$51K -$17.7K -10,160 -22%
UBS Group
19
UBS Group
Switzerland
$48.1K -$548K -313,907 -90%
PAM
20
Panagora Asset Management
Massachusetts
$47K +$59K +33,814 New
Squarepoint
21
Squarepoint
New York
$38.2K +$2.29K +1,310 +5%
PCM
22
Prelude Capital Management
New York
$33.4K -$41.9K -24,000 -50%
MG
23
Marex Group
$27.8K +$17.4K +10,000 +100%
Dimensional Fund Advisors
24
Dimensional Fund Advisors
Texas
$25.4K – – –
Bank of America
25
Bank of America
North Carolina
$23K -$1.63K -934 -5%
1
2 3

ACRV Hedge Fund Activity: Q1 2026 in Review

44 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Acrivon Therapeutics (ACRV) for Q1 2026, worth a combined $22.6M — down 50% from $44.9M a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of ACRV and 10 opened new positions — a net loss of 3 holders — while 11 trimmed existing stakes and 11 added.

The largest buyer was Acadian Asset Management, adding an estimated $462K. The largest seller was Citadel Advisors, exiting entirely with an estimated $3.96M sold.

  • 44 institutional investors held Acrivon Therapeutics (ACRV) as of Q1 2026, down from 48 in Q4 2025.
  • Funds reported $22.6M of Acrivon Therapeutics stock for Q1 2026, down 50% quarter-over-quarter.
  • 10 funds opened new Acrivon Therapeutics positions in Q1 2026 and 13 closed out, a net change of -3 holders.
  • The largest Acrivon Therapeutics buyer in Q1 2026 was Acadian Asset Management, an estimated $462K added.
  • The largest Acrivon Therapeutics seller in Q1 2026 was Citadel Advisors, an estimated $3.96M sold.

Based on aggregated 13F filings for Q1 2026.